Clinical Trials Sponsored by UNICEF - Venezuela

Total 5467 results

United Therapeutics

Terminated

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

Pulmonary Hypertension Associated With HFpEF

United States
United Laboratories

Completed

Astaxanthin (2 mg) + Lycopene (1.8 mg) + D-Alpha-Tocopherol (10 IU) For The Treatment Of Skin Aging

Skin Aging | Wrinkles

Philippines
United Laboratories

Completed

Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos

Pediculosis Capitis

Philippines
United Therapeutics

Terminated

Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Australia
United Therapeutics

Completed

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Neuroblastoma

United States
United Pharmaceuticals

Completed

Study on the Tolerance and Efficacy of a New Anti Regurgitation Formula (SONAR)

Gastroesophageal Reflux

Belgium, France
United Therapeutics

Withdrawn

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

PAH

United States
Unimed Pharmaceuticals

Completed

A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome (UNCNT)

Menopausal Syndrome

Korea, Republic of
United Therapeutics

Terminated

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Primary Refractory Neuroblastoma

United States
United Therapeutics

Completed

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

Pulmonary Arterial Hypertension

United States
United Therapeutics

Withdrawn

Safety and Efficacy of Inhaled Treprostinil in Patients With PAH (INTREPID)

Pulmonary Arterial Hypertension
United Therapeutics

Withdrawn

Inhaled Treprostinil for PAH: Open-label Extension (INTREPID - OL)

Pulmonary Arterial Hypertension
United Therapeutics

Completed

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States
United Therapeutics

Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Interstitial Lung Disease | Progressive Pulmonary Fibrosis

United States, Canada
United Therapeutics

Recruiting

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER)

Pulmonary Hypertension | Interstitial Lung Disease

United States
United BioPharma

Not yet recruiting

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

HIV-1-infection
United BioPharma

Not yet recruiting

UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

HIV-1 Infection
United BioPharma

Not yet recruiting

A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621

Genital Herpes
United BioPharma

Not yet recruiting

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

HIV-1 Infection
United Therapeutics

Completed

TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) (TRUST-2)

Pulmonary Arterial Hypertension
United Therapeutics

Completed

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Pulmonary Arterial Hypertension

United States
United BioPharma

Completed

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

HIV-1 Infection

Taiwan
United Therapeutics

Terminated

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) (PERFECT)

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Israel, Argentina, Puerto Rico
United Therapeutics

Terminated

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Pulmonary Hypertension | Interstitial Lung Disease | Combined Pulmonary Fibrosis and Emphysema

United States, Puerto Rico
United Therapeutics

Completed

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Korea, Republic of, United States, Australia, Austria, Taiwan, China, Israel, Canada, India, Germany, Singapore, United Kingdom, Brazil, Italy, Netherlands, Argentina, Sweden, Chile, Denmark, France, Greece, Mexico, Poland
United Therapeutics

Completed

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension (FREEDOM-EXT)

Pulmonary Arterial Hypertension

United States, Canada, India, United Kingdom, Spain, Israel, Australia, Belgium, France, Austria, China, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Sweden
United Therapeutics

Completed

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Canada, Spain, Australia, Korea, Republic of, France, United Kingdom, Thailand, Malaysia, Hungary, Poland, Taiwan, Philippines, Hong Kong, Lithuania, Georgia, Bulgaria, India, Italy, Romania, Russian Federation, Slo... and more
United BioPharma

Withdrawn

the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

HIV-1 Infection
United Therapeutics

Completed

Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy (FREEDOM-EV)

Pulmonary Arterial Hypertension

Korea, Republic of, United States, Australia, Austria, Taiwan, China, Israel, Canada, India, Germany, Singapore, United Kingdom, Brazil, Italy, Netherlands, Argentina, Sweden, Chile, Denmark, France, Greece, Mexico, Poland
United Therapeutics

Completed

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

PAH

United States
United Therapeutics

Completed

Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) (RAPID)

Pulmonary Arterial Hypertension
United Therapeutics

Withdrawn

Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

Pulmonary Hypertension Associated With Sickle Cell Disease
United Therapeutics

Completed

Remodulin® to Oral Treprostinil Transition

Pulmonary Arterial Hypertension

United States
United Therapeutics

Withdrawn

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Pulmonary Fibrosis | Pulmonary Hypertension

United States
United Pharmaceuticals

Completed

Efficacy of a New Thickened Extensively Hydrolyzed Formula (ALLAR)

Protein Allergy | Cow's Milk Protein Hypersensitivity

Slovenia, Belgium, Greece, Kuwait, Lebanon
United Pharmaceuticals

Completed

A Double-blind Randomized Controlled Trial of a Thickened Amino-acid-based Formula in Children Allergic to Cow's Milk and to Protein Hydrolysates

Cow Milk Allergy

France
United Therapeutics

Completed

Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

Pulmonary Arterial Hypertension

United States, Puerto Rico
United Pharmaceuticals

Completed

Evaluation of the Efficacy of a New Formula in Infants With Cow's Milk Protein Allergy (Paradice)

Milk Hypersensitivity | Food Sensitivity | Protein Allergy

Belgium
Unimed Pharmaceuticals

Completed

Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid.

Healthy
United Therapeutics

Terminated

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

Peripheral Vascular Disease | Critical Limb Ischemia | Foot Ulcers | Rest Leg Pain

United States
United Therapeutics

Completed

The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil

Pulmonary Arterial Hypertension | Renal Dysfunction

United States
United Biomedical

Completed

Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults

HIV-1 Infection in Adults (Asymptomatic)

Taiwan
United Therapeutics

Completed

Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Effect of Food on the Pharmacokinetics of Oral Treprostinil

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States
United BioPharma

Recruiting

A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Taiwan
United Laboratories

Recruiting

Lactoferrin + Vitamin E + Zinc for Hormonal Acne

Hormonal Acne

Philippines
United Therapeutics

Recruiting

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON)

Idiopathic Pulmonary Fibrosis | Interstitial Lung Disease

United States, Canada
United Therapeutics

Recruiting

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Cardiovascular Diseases | Vascular Diseases | Lung Diseases | Hypertension | Connective Tissue Diseases | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Hypertension, Pulmonary | Pulmonary Hypertension | PAH | Respiratory Tract Disease

United States, Australia, Austria, Italy, Taiwan, Spain, Korea, Republic of, Canada, United Kingdom, Singapore, Argentina, Germany, France, Belgium, Mexico, Brazil, Hungary, Bulgaria, Chile, Czechia, Denmark, Greece, Israel, Netherlands, Pola... and more
United Therapeutics

Terminated

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Persistent Pulmonary Hypertension of the Newborn

United States

Clinical Trials Sponsored by UNICEF - Venezuela

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations